Dr Myers on Mitigation Strategies for Ocular AEs in Platinum-Resistant Ovarian Cancer

“[It is] very important to tell women that they can live longer with [mirvetuximab soravtansine] when they have platinum-resistant ovarian cancer that is Frα positive, and they don’t have to sacrifice QOL.”

Tashanna K. Myers, MD, a professor of obstetrics and gynecology at the UMass Chan Medical School—Baystate, discussed the clinical implications of findings from a health-related quality of life (HRQOL) analysis of the phase 3 MIRASOL trial (NCT04209855) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with Frα-positive, platinum-resistant ovarian cancer.

This study found that treatment-emergent ocular adverse effects (AEs)—including blurred vision and keratopathy—among patients who received mirvetuximab soravtansine in MIRASOL were not significantly associated with HRQOL detriments. Additionally, investigators saw no significant QOL differences between patients with treatment-emergent blurred vision or keratopathy and those who did not experience treatment-emergent ocular AEs. Furthermore, a broadened sensitivity analysis showed no statistically significant differences between select patient-reported HRQOL outcomes among patients who experienced any treatment-emergent ocular AEs and those who did not experience treatment-emergent ocular AEs.

Ocular AE mitigation strategies include close collaboration between oncologists and ophthalmologists, as well as the use of lubricating eye drops and/or steroid eye drops during treatment, Myers said. Notably, in this study, 93% of patients achieved complete or partial resolution of ocular AEs by the data cutoff date, she explained.

These findings are exciting because the goal of ovarian cancer treatment is for patients to live longer without detriment to their QOL, Myers emphasized. Although ocular AEs were a relatively novel phenomenon when mirvetuximab soravtansine was first under investigation, oncologists better understand these toxicities now, she asserted. Accordingly, it is important to counsel patients with FRα-positive platinum-resistant ovarian cancer on the survival and QOL benefits associated with this agent, she concluded.

Disclosures: Myers reported receiving grants or contracts from GSK; receiving payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from ImmunoGen, Inc; and participating in a Data Safety Monitoring Board or Advisory Board at Gilead.